---
id: insilico-pharma-ai
slug: insilico-pharma-ai
entity_type: commercial
status: operational
data_completeness: high
last_researched: 2025-12-23
researcher: AI Assistant
version: 1.1
name: Insilico Medicine Pharma.AI Platform
description: End-to-end AI-driven drug discovery and development platform integrating biology, chemistry, and clinical development using generative artificial intelligence
mission: To extend healthy and productive longevity for all by transforming drug discovery and development through generative artificial intelligence, significantly reducing the time and cost to deliver life-saving medicines to patients. The company aims to accelerate the identification of novel drug targets and design of new molecular structures using AI-driven platforms.
entity_data:
  focus: AI-driven drug discovery and development using generative artificial intelligence to accelerate the identification of novel drug targets and design of new molecular structures
  founded: 2014
  website: "https://insilico.com/"
  industry: Biotechnology
  employees:
  as_of: 2025
  range: 201-500
  legal_name: Insilico Medicine, Inc.
taxonomy:
  geography: USA
  ai_approach:
  - Generative AI
  ai_technology:
  - Generative AI
  primary_focus:
  - AI-Driven Drug Discovery
  aging_approach:
  - Target Discovery
  - Molecule Design
  target_biology:
  - General Aging/Longevity
  - Fibrosis
  ai_architecture: []
  ai_specialization: []
  development_stage: operational
  organization_type: commercial
  organization_subtype: operational
  therapeutic_modality:
  - Small Molecules
organizations:
  -
    name: Eli Lilly
    role: partner
    org_type: company
    website: "https://www.lilly.com/"
    status: operational
    role_description: Research and licensing collaboration partner
    contribution_description: Collaboration to discover and advance innovative therapies using Pharma.AI platform
  -
    name: Syngenta Group
    role: partner
    org_type: company
    website: "https://www.syngentagroup.com/"
    status: operational
    role_description: Collaboration partner
    contribution_description: Collaboration to leverage AI for discovery of novel crop protection solutions
  -
    name: Insilico Medicine
    role: primary
    org_type: company
    legal_name: Insilico Medicine, Inc.
    founded: 2014
    website: "https://insilico.com/"
    status: operational
    role_description: Primary developer and operator
    contribution_description: Developer and operator of Pharma.AI platform
products:
  -
    name: Mitochondrial Aging Peptides
    type: therapy
    status: operational
    development_stage: clinical_trials
  -
    name: GLP-1 Receptor Agonists
    type: drug
    status: operational
    development_stage: discovery
  -
    name: ISM8969
    type: drug
    status: operational
    development_stage: preclinical
  -
    name: Rentosertib
    type: drug
    status: operational
  -
    name: Pharma.AI Platform
    type: platform
    status: operational
links:
  -
    url: "https://arxiv.org/abs/2101.09050"
    type: scientific_publication
    title: "Chemistry42: An AI-based platform for de novo molecular design"
  -
    url: "https://www.biopharmatrend.com/news/insilico-medicine-reports-preclinical-benchmarks-for-ai-designed-therapeutics-1137/"
    type: article
    title: Insilico Medicine Reports Preclinical Benchmarks
  -
    url: "https://www.syngentagroup.com/sites/default/files/2023-04/210203-syngenta-insilico-collaboration-en.pdf"
    type: press_release
    title: Syngenta and Insilico Medicine Collaboration
  -
    url: "https://aws.amazon.com/solutions/case-studies/insilico-customer-case-study/"
    type: case_study
    title: Insilico Medicine Accelerates Drug Discovery Using Amazon SageMaker
  -
    url: "https://blogs.nvidia.com/blog/2023/06/27/insilico-medicine-uses-generative-ai-to-accelerate-drug-discovery/"
    type: article
    title: Insilico Medicine Uses Generative AI to Accelerate Drug Discovery
  -
    url: "https://www.prnewswire.com/news-releases/ai-for-good-insilico-medicine-hosts-imgaia-product-launch-event-302205210.html"
    type: press_release
    title: "AI for Good: Insilico Medicine Hosts IMGAIA Product Launch Event"
  -
    url: "https://www.prnewswire.com/news-releases/insilico-medicine-applauded-by-frost--sullivan-for-enabling-rapid-and-cost-effective-drug-discovery-and-development-with-its-pharmaai-platform-301467147.html"
    type: press_release
    title: Insilico Medicine Applauded by Frost & Sullivan
  -
    url: "https://www.prnewswire.com/news-releases/insilico-and-lilly-enter-a-research--licensing-collaboration-to-advance-ai-driven-drug-discovery-302610234.html"
    type: press_release
    title: Insilico and Lilly Enter Research & Licensing Collaboration
  -
    url: "https://www.prnewswire.com/news-releases/insilico-medicine-secures-110-million-series-e-financing-to-advance-ai-driven-drug-discovery-innovation-302401040.html"
    type: press_release
    title: Insilico Medicine Secures $110 Million Series E Financing
  -
    url: "https://insilico.com/news/2ky5zn0fs1-insilico-medicine-unveils-winter-edition"
    type: press_release
    title: Insilico Medicine unveils winter edition of Pharma.AI
  -
    url: "https://en.wikipedia.org/wiki/Insilico_Medicine"
    type: reference
    title: Insilico Medicine - Wikipedia
  -
    url: "https://pharma.ai/"
    type: website
    title: Pharma.AI - Official Platform Website
  -
    url: "https://www.prnewswire.com/apac/news-releases/first-drug-discovered-and-designed-with-generative-ai-enters-phase-ii-trials-with-first-patients-dosed-301862737.html"
    type: press_release
    title: First Drug Discovered with Generative AI Enters Phase II Trials
---

# Insilico Medicine Pharma.AI Platform

## Description

End-to-end AI-driven drug discovery and development platform integrating biology, chemistry, and clinical development using generative artificial intelligence

## Mission

To extend healthy and productive longevity for all by transforming drug discovery and development through generative artificial intelligence, significantly reducing the time and cost to deliver life-saving medicines to patients. The company aims to accelerate the identification of novel drug targets and design of new molecular structures using AI-driven platforms.

## Company Information

**Legal Name**: Insilico Medicine, Inc.
**Founded**: 2014
**Industry**: Biotechnology
**Employees**: {"as_of":"2025","range":"201-500"}
**Focus**: AI-driven drug discovery and development using generative artificial intelligence to accelerate the identification of novel drug targets and design of new molecular structures
**Website**: https://insilico.com/

## AI Methods

- Generative Adversarial Networks (GANs)
- Reinforcement Learning (RL)
- Transformer Neural Networks
- Large Language Models (LLMs)
- Deep Generative Models
- Graph Neural Networks (GNNs)
- Binding Prediction
- Multi-omics Integration
- Machine Learning
- Deep Learning

## Platforms

- Pharma.AI
- PandaOmics
- Chemistry42
- Generative Biologics
- Science42: DORA
- Nach01
- InClinico
- Medicine42

## System Architecture

```yaml
pandaomics:
  ai_methods:
  - Multi-omics Integration
  - Machine Learning
  - Deep Learning
  - Transcriptomics Analysis
  - Proteomics Analysis
  data_types:
  - Transcriptomics
  - Proteomics
  - Clinical data
  - Pathway data
  capabilities:
  - Novel target identification from multi-omics data
  - Biomarker discovery and validation
  - Pathway analysis and target prioritization
chemistry42:
  ai_methods:
  - Generative Adversarial Networks (GANs)
  - Reinforcement Learning (RL)
  - Deep Generative Models
  - Transformer Neural Networks
  - Graph Neural Networks (GNNs)
  model_count: 40+ generative models integrated
  key_features:
  - De novo molecular design
  - Multi-objective optimization
  - MolSpace for chemical space exploration
  - PACE (Patent Analysis)
  - Alchemistry engine with RBFE calculations
```

## Technical Workflow

```yaml
workflow:
  - "Target Discovery: PandaOmics analyzes multi-omics data to identify novel targets"
  - "Molecule Design: Chemistry42 generates and optimizes molecular candidates using 40+ generative models"
  - "Multi-objective Optimization: RL-based optimization for efficacy, selectivity, and ADMET properties"
  - "Synthesis Prioritization: AI-guided selection of molecules for synthesis"
  - "Experimental Validation: In vitro and in vivo testing of prioritized candidates"
  - "Clinical Development: InClinico/Medicine42 optimize clinical trial design"
```

## Performance Metrics

```yaml
productivity:
  ind_clearances: 10
  molecules_per_program: 60-200 synthesized and tested
  clinical_trials_completed: Multiple trials for two advanced pipelines
  preclinical_candidates_nominated: 20+ since 2021
platform_adoption:
  external_users: Pharmaceutical companies worldwide
  commercial_availability: Yes - available for licensing
time_acceleration:
  target_to_phase_1: <30 months demonstrated (Rentosertib case)
  preclinical_candidate_nomination: 12-18 months (vs. 2.5-4 years traditional) - 3-4x acceleration
```

## Lessons Learned

### Achievements

- Successfully demonstrated end-to-end AI-driven drug development from target identification to clinical validation
- Proved that AI-discovered targets AND AI-designed molecules can show efficacy in humans (Rentosertib Phase 2a)
- Reduced drug discovery timeline from 10-15 years to 12-18 months for preclinical candidate nomination
- Achieved target discovery to Phase 1 in <30 months (vs. 10+ years traditional)
- Nominated over 20 preclinical candidates since 2021 with only 60-200 molecules synthesized per program (vs. thousands in traditional methods)
- Established Pharma.AI as a commercially viable platform with multiple major pharma partnerships

### Impact on Field

Insilico Medicine has been a pioneer in demonstrating that generative AI can successfully accelerate and transform drug discovery. The company proved that AI can not only discover novel targets but also design effective molecules, with Rentosertib being the first AI-discovered target AND AI-designed molecule to show efficacy in humans. This validates the end-to-end AI pharma model and establishes a template for rapid development of multiple aging interventions. The platform's success has attracted major pharma partnerships worth over $4.5 billion, demonstrating industry confidence in AI-driven drug discovery.

## Organizations

### Eli Lilly
**Role in Project**: partner
**Role Description**: Research and licensing collaboration partner
**Contribution**: Collaboration to discover and advance innovative therapies using Pharma.AI platform
**Organization Type**: company
**Status**: operational
**Website**: https://www.lilly.com/
**Description**: Global pharmaceutical company
**Focus**: Pharmaceutical research and development

### Syngenta Group
**Role in Project**: partner
**Role Description**: Collaboration partner
**Contribution**: Collaboration to leverage AI for discovery of novel crop protection solutions
**Organization Type**: company
**Status**: operational
**Website**: https://www.syngentagroup.com/
**Description**: Agricultural technology company
**Focus**: Crop protection solutions and sustainable agriculture

### Insilico Medicine
**Legal Name**: Insilico Medicine, Inc.
**Role in Project**: primary
**Role Description**: Primary developer and operator
**Contribution**: Developer and operator of Pharma.AI platform
**Organization Type**: company
**Status**: operational
**Founded**: 2014
**Website**: https://insilico.com/
**Description**: AI-driven drug discovery and development using generative artificial intelligence
**Focus**: AI-driven drug discovery and development

## Locations

### Cambridge, USA
**Type**: headquarters
**Address**: 1000 Massachusetts Avenue, Cambridge, MA, USA
**City**: Cambridge
**State/Region**: Massachusetts
**Country**: USA
**Organizations**: Insilico Medicine

### New York, USA
**Type**: office
**Address**: The Cure by Deerfield, New York, NY, USA
**City**: New York
**State/Region**: New York
**Country**: USA
**Organizations**: Insilico Medicine

### Hong Kong, Hong Kong
**Type**: office
**Address**: Unit 307A, Core Building 1, 1 Science Park East Avenue, Hong Kong Science Park, Pak Shek Kok, New Territories, Hong Kong
**City**: Hong Kong
**Country**: Hong Kong
**Organizations**: Insilico Medicine

## Products

### Mitochondrial Aging Peptides
**Type**: therapy
**Status**: operational
**Development Stage**: clinical_trials
**Role in Project**: secondary
**Relationship Description**: Mitochondrial aging peptides discovered using Generative Biologics module
**Description**: 3 novel peptides discovered that reverse mitochondrial aging in mice. Discovered using Generative Biologics module with generative diffusion models for peptides and biologics. Phase I trials announced October 2025
**Mechanism of Action**: Mitochondrial function restoration
**Target**: Mitochondrial pathways
**Pathway**: Mitochondrial aging
**Indications**: [
  {
    "primary": "Age-related mitochondrial dysfunction"
  }
]
**Clinical Trials**:
```yaml
-
  phase: Phase 1
  status: Announced
  indication: Mitochondrial aging
  start_date: 2025-10
```

### GLP-1 Receptor Agonists
**Type**: drug
**Status**: operational
**Development Stage**: discovery
**Role in Project**: secondary
**Relationship Description**: GLP-1 receptor agonists developed using Pharma.AI platform
**Description**: Oral GLP-1 receptor agonists for cardiometabolic diseases. Part of portfolio of eight novel small-molecule drug candidates targeting aging-related pathways announced in 2025
**Mechanism of Action**: GLP-1 receptor agonist
**Target**: GLP-1 receptor
**Pathway**: Metabolic pathway
**Indications**: [
  {
    "primary": "Cardiometabolic diseases"
  }
]

### ISM8969
**Type**: drug
**Status**: operational
**Development Stage**: preclinical
**Role in Project**: secondary
**Relationship Description**: NLRP3 inflammasome inhibitor developed using Pharma.AI platform
**Description**: Brain-penetrant NLRP3 inflammasome inhibitor for inflammatory diseases. Reached IND-enabling studies in 2025
**Mechanism of Action**: NLRP3 inflammasome inhibitor
**Target**: NLRP3 inflammasome
**Pathway**: Inflammatory pathway
**Indications**: [
  {
    "primary": "Inflammatory diseases (age-related)"
  }
]

### Rentosertib
**Alternative Names**: ISM001-055, INS018_055
**Type**: drug
**Status**: operational
**Role in Project**: secondary
**Relationship Description**: Example product developed using Pharma.AI platform - see insilico-rentosertib-tnik for details
**Description**: TNIK (Traf2- and Nck-interacting kinase) inhibitor for Idiopathic Pulmonary Fibrosis. First AI-discovered target AND AI-designed molecule to show efficacy in humans. For detailed information see case study: insilico-rentosertib-tnik
**Mechanism of Action**: TNIK inhibitor
**Target**: TNIK protein
**Pathway**: TGF-Î² signaling pathway, fibrosis pathway
**Indications**: [
  {
    "primary": "Idiopathic Pulmonary Fibrosis (IPF)"
  }
]

### Pharma.AI Platform
**Alternative Names**: Pharma.AI
**Type**: platform
**Status**: operational
**Role in Project**: primary
**Relationship Description**: Primary product - end-to-end AI-driven drug discovery platform
**Description**: End-to-end AI-driven drug discovery and development platform integrating biology, chemistry, and clinical development. Commercially available platform designed to improve the quality and productivity of pharmaceutical research.
**Components**:
```yaml
-
  name: PandaOmics
  description: AI-powered engine for target and biomarker discovery
  technical_details:
  ai_methods:
  - Multi-omics Integration
  - Machine Learning
  - Deep Learning
  - Transcriptomics Analysis
  - Proteomics Analysis
  data_types:
  - Transcriptomics
  - Proteomics
  - Clinical data
  - Pathway data
-
  name: Chemistry42
  description: Generative chemistry platform utilizing deep generative models and reinforcement learning
  technical_details:
  ai_methods:
  - Generative Adversarial Networks (GANs)
  - Reinforcement Learning (RL)
  - Deep Generative Models
  - Transformer Neural Networks
  - Graph Neural Networks (GNNs)
  model_count: 40+ generative models integrated
  performance_metrics:
  success_rate: Over 20 preclinical candidates nominated since 2021
  molecules_synthesized_per_program: 60-200 molecules
  average_time_to_preclinical_candidate: 12-18 months (vs. 2.5-4 years traditional)
-
  name: Generative Biologics
  description: AI-driven platform for de novo protein engineering and biologics design
-
  name: "Science42: DORA"
  description: Multi-agent generative research assistant powered by LLMs
-
  name: Nach01
  description: Multimodal foundation model for natural and chemical languages
-
  name: InClinico
  note: "See case study: insilico-adaptive-trials"
  description: AI-powered tool for predicting clinical trial outcomes
-
  name: Medicine42
  note: "See case study: insilico-adaptive-trials"
  description: Clinical trial analysis and prediction platform
```
**Technical Details**:
```yaml
updates:
  -
    date: 2025-12-10
    version: Winter 2025 Edition
    features:
    - Enhanced scientific rigor and enterprise-grade security
    - MolSpace for chemical space exploration in Chemistry42
    - PACE (Patent Analysis) feature in Chemistry42
    - New LLM scores in PandaOmics
  -
    date: 2025-07-10
    version: Summer 2025 Updates
    features:
    - Integration of Nach01 foundation model via AWS Marketplace
    - Major update to Chemistry42 Alchemistry engine
    - Enhanced protein-ligand molecular dynamics analysis
launch_date: 2022-11-14
achievements:
  - Nominated over 20 developmental/preclinical candidates since 2021
  - Received IND clearance for 10 molecules
  - Completed multiple human clinical trials for two advanced pipelines with positive results
  - Reduced average time to preclinical candidate nomination to 12-18 months (vs. 2.5-4 years traditional)
  - First AI-discovered target AND AI-designed molecule (Rentosertib) to show efficacy in humans
  - Platform commercially available and used by pharmaceutical companies worldwide
technologies:
  - Generative Adversarial Networks (GANs)
  - Reinforcement Learning (RL)
  - Transformer Neural Networks
  - Large Language Models (LLMs)
  - Deep Generative Models
  - Graph Neural Networks (GNNs)
  - Binding Prediction
```

## Key People

### Alex Aliper
**Participation Type**: leadership
**Role in Project**: President
**Affiliations**: Insilico Medicine
**Participation Period**: Unknown-present
**Expertise**: AI and drug discovery platform development
**Biography**: President at Insilico Medicine (Unknown-present). AI and drug discovery platform development.

### Alex Zhavoronkov
**Title**: PhD
**Participation Type**: founder
**Role in Project**: Founder and CEO
**Affiliations**: Insilico Medicine
**Participation Period**: 2014-present
**Expertise**: AI in drug discovery, biotechnology, aging research; AI in Drug Discovery, Aging Research, Machine Learning
**Biography**: PhD, pioneer in applying AI to biotechnology and drug discovery. Founded Insilico Medicine in 2014 to transform drug discovery using generative AI. Founder and CEO (2014-present).

### Feng Ren
**Participation Type**: leadership
**Role in Project**: Chief Scientific Officer
**Affiliations**: Insilico Medicine
**Participation Period**: Unknown-present
**Expertise**: Scientific leadership in AI-driven drug discovery
**Biography**: Chief Scientific Officer at Insilico Medicine (Unknown-present). Scientific leadership in AI-driven drug discovery.

## Links

### [Chemistry42: An AI-based platform for de novo molecular design](https://arxiv.org/abs/2101.09050)
**Type**: scientific_publication
**Relevance**: primary
**Category**: publication
**Publication Date**: 2021-01-22
**Description**: Research paper on Chemistry42 platform, part of Pharma.AI ecosystem

### [Insilico Medicine Reports Preclinical Benchmarks](https://www.biopharmatrend.com/news/insilico-medicine-reports-preclinical-benchmarks-for-ai-designed-therapeutics-1137/)
**Type**: article
**Relevance**: secondary
**Category**: source
**Publication Date**: 2024-01-01
**Description**: Article reporting preclinical benchmarks showing 13-month average time to candidate nomination

### [Syngenta and Insilico Medicine Collaboration](https://www.syngentagroup.com/sites/default/files/2023-04/210203-syngenta-insilico-collaboration-en.pdf)
**Type**: press_release
**Relevance**: primary
**Category**: source
**Publication Date**: 2021-02-03
**Description**: Press release about collaboration with Syngenta

### [Insilico Medicine Accelerates Drug Discovery Using Amazon SageMaker](https://aws.amazon.com/solutions/case-studies/insilico-customer-case-study/)
**Type**: case_study
**Relevance**: secondary
**Category**: source
**Description**: AWS case study on Insilico use of Amazon SageMaker

### [Insilico Medicine Uses Generative AI to Accelerate Drug Discovery](https://blogs.nvidia.com/blog/2023/06/27/insilico-medicine-uses-generative-ai-to-accelerate-drug-discovery/)
**Type**: article
**Relevance**: primary
**Category**: source
**Publication Date**: 2023-06-27
**Description**: NVIDIA blog article about Insilico AI-driven drug discovery

### [AI for Good: Insilico Medicine Hosts IMGAIA Product Launch Event](https://www.prnewswire.com/news-releases/ai-for-good-insilico-medicine-hosts-imgaia-product-launch-event-302205210.html)
**Type**: press_release
**Relevance**: primary
**Category**: source
**Publication Date**: 2024-07-24
**Description**: Press release about IMGAIA product launch

### [Insilico Medicine Applauded by Frost & Sullivan](https://www.prnewswire.com/news-releases/insilico-medicine-applauded-by-frost--sullivan-for-enabling-rapid-and-cost-effective-drug-discovery-and-development-with-its-pharmaai-platform-301467147.html)
**Type**: press_release
**Relevance**: primary
**Category**: source
**Publication Date**: 2022-01-25
**Description**: Press release about Frost & Sullivan award

### [Insilico and Lilly Enter Research & Licensing Collaboration](https://www.prnewswire.com/news-releases/insilico-and-lilly-enter-a-research--licensing-collaboration-to-advance-ai-driven-drug-discovery-302610234.html)
**Type**: press_release
**Relevance**: primary
**Category**: source
**Publication Date**: 2025-11-10
**Description**: Press release announcing collaboration with Eli Lilly

### [Insilico Medicine Secures $110 Million Series E Financing](https://www.prnewswire.com/news-releases/insilico-medicine-secures-110-million-series-e-financing-to-advance-ai-driven-drug-discovery-innovation-302401040.html)
**Type**: press_release
**Relevance**: primary
**Category**: source
**Publication Date**: 2025-03-13
**Description**: Press release announcing Series E funding round

### [Insilico Medicine unveils winter edition of Pharma.AI](https://insilico.com/news/2ky5zn0fs1-insilico-medicine-unveils-winter-edition)
**Type**: press_release
**Relevance**: primary
**Category**: source
**Publication Date**: 2025-12-10
**Description**: Press release announcing Winter 2025 Edition of Pharma.AI

### [Insilico Medicine - Wikipedia](https://en.wikipedia.org/wiki/Insilico_Medicine)
**Type**: reference
**Relevance**: secondary
**Category**: reference
**Description**: Wikipedia page about Insilico Medicine

### [Pharma.AI - Official Platform Website](https://pharma.ai/)
**Type**: website
**Relevance**: primary
**Category**: source
**Description**: Official Pharma.AI platform website

### [First Drug Discovered with Generative AI Enters Phase II Trials](https://www.prnewswire.com/apac/news-releases/first-drug-discovered-and-designed-with-generative-ai-enters-phase-ii-trials-with-first-patients-dosed-301862737.html)
**Type**: press_release
**Relevance**: primary
**Category**: publication
**Publication Date**: 2023-06-27
**Description**: Press release announcing Phase II trials initiation

## Financials

### funding
**Amount**: $110M USD
**Amount (Numeric)**: 110000000
**Funding Date**: 2025-03-13
**Source**: Value Partners Group
**Funding Type**: Series E
**Description**: Series E funding round led by Value Partners Group
**Details**:
```yaml
purpose: "Advance Insilico's innovative drug pipeline and AI platform developments, including refining AI models, expanding automated labs, and advancing clinical validation of flagship candidates"
investors:
  - Value Partners Group
  - Other industry and technology-focused investors
round_type: Series E
lead_investor: Value Partners Group
```

### funding
**Amount**: $255M USD
**Amount (Numeric)**: 255000000
**Funding Date**: 2021-06-22
**Source**: Warburg Pincus
**Funding Type**: Series C
**Description**: Series C funding round led by Warburg Pincus
**Details**:
```yaml
purpose: Funding to advance AI-driven drug discovery platform and pipeline development
investors:
  - Warburg Pincus
  - Other investors
round_type: Series C
lead_investor: Warburg Pincus
```

## Events

### Insilico Medicine Founded
**Date**: 2014-01-01
**Type**: company_founded
**Description**: Insilico Medicine founded by Alex Zhavoronkov
**Details**:
```yaml
founder: Alex Zhavoronkov
```

### First Generative AI Concept Publication
**Date**: 2016-01-01
**Type**: technology_development
**Description**: Publication of concept for using generative AI for molecule design in peer-reviewed journal
**Details**:
```yaml
milestone: First concept publication
```

### Series C Funding: $255M
**Date**: 2021-06-22
**Type**: funding
**Description**: Announced $255 million Series C funding round led by Warburg Pincus
**Details**:
```yaml
round: Series C
amount: $255 million
lead_investor: Warburg Pincus
```

### Frost & Sullivan Entrepreneurial Company of the Year
**Date**: 2022-01-25
**Type**: award
**Description**: Received 2021 Entrepreneurial Company of the Year Award from Frost & Sullivan
**Details**:
```yaml
award: Entrepreneurial Company of the Year Award
category: AI-enabled drug discovery industry
organization: Frost & Sullivan
```

### Pharma.AI Platform Launch
**Date**: 2022-11-14
**Type**: platform_launch
**Description**: Official launch of Pharma.AI platform
**Details**:
```yaml
platform: Pharma.AI
```

### Rentosertib Enters Phase II Trials
**Date**: 2023-06-27
**Type**: clinical_milestone
**Description**: First drug discovered and designed with generative AI (INS018_055/Rentosertib) entered Phase II clinical trials
**Details**:
```yaml
drug: INS018_055/Rentosertib
phase: Phase II
indication: Idiopathic pulmonary fibrosis
```

### IMGAIA Product Launch Event
**Date**: 2024-07-24
**Type**: product_launch
**Description**: Hosted IMGAIA product launch event, announcing sustainability benchmarking initiative and new generative AI features
**Details**:
```yaml
event: IMGAIA Product Launch
```

### Series E Funding: $110M
**Date**: 2025-03-13
**Type**: funding
**Description**: Secured $110 million Series E financing led by Value Partners Group
**Details**:
```yaml
round: Series E
amount: $110 million
lead_investor: Value Partners Group
```

### Pharma.AI Summer 2025 Updates
**Date**: 2025-07-10
**Type**: platform_update
**Description**: Pharma.AI Summer 2025 Updates: Integration of Nach01 foundation model and major updates to Chemistry42
**Details**:
```yaml
updates:
  - Nach01 integration
  - Chemistry42 Alchemistry engine update
platform: Pharma.AI
```

### Mitochondrial Aging Peptides Phase I Trials
**Date**: 2025-10-01
**Type**: clinical_milestone
**Description**: Announced Phase I trials for 3 novel peptides reversing mitochondrial aging in mice
**Details**:
```yaml
phase: Phase I
product: Mitochondrial aging peptides
discovery_platform: Generative Biologics module
```

### Eli Lilly Collaboration
**Date**: 2025-11-10
**Type**: partnership
**Description**: Entered research and licensing collaboration with Eli Lilly
**Details**:
```yaml
partner: Eli Lilly
deal_value: Over $100 million including upfront and milestone payments plus tiered royalties
```

### Pharma.AI Winter 2025 Edition
**Date**: 2025-12-10
**Type**: platform_update
**Description**: Unveiled Winter 2025 Edition of Pharma.AI with enhanced features
**Details**:
```yaml
edition: Winter 2025
features:
  - Enhanced scientific rigor
  - Enterprise-grade security
  - MolSpace
  - PACE
platform: Pharma.AI
```

## Partnerships

### commercial
**Date**: 2021-02-03
**Focus**: Agricultural applications of AI platform
**Description**: Collaboration to leverage AI for discovery and development of novel crop protection solutions and sustainable agriculture applications
**Partner Organizations**:
- Syngenta Group (partner)
  - Collaboration partner for agricultural applications
**Details**:
```yaml
application: Crop protection and sustainable agriculture
```

### commercial
**Date**: 2025-11-10
**Focus**: AI-driven drug discovery using Pharma.AI platform
**Description**: Research and licensing collaboration to combine Insilico Pharma.AI platform with Lilly expertise to discover and advance innovative therapies
**Partner Organizations**:
- Eli Lilly (partner)
  - Collaboration partner utilizing Pharma.AI for drug discovery
**Details**:
```yaml
lilly_role: Provide expertise and targets for drug discovery
insilico_role: Utilize Pharma.AI to generate, design, and optimize candidate compounds
financial_terms: Insilico eligible to receive over $100 million, including upfront and milestone payments, and tiered royalties on net sales
```

### technology
**Focus**: AI model acceleration
**Description**: Technology partnership to utilize Amazon SageMaker for model training
**Details**:
```yaml
impact: Reduced time to implement new ML models from 50 days to 3 days
status: Ongoing
technology: Amazon SageMaker
```
